Sirnaomics Ltd.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2257)

VOLUNTARY ANNOUNCEMENT

RNAIMMUNE RECEIVES IND CLEARANCE FROM FDA FOR PHASE I CLINICAL STUDY OF RV-1730 COVID-19 BOOSTER VACCINE

The board (the "**Board**") of directors (the "**Directors**") of Sirnaomics Ltd. (the "**Company**", together with its subsidiaries, the "**Group**" or "**Sirnaomics**") hereby informs the shareholders and potential investors of the Company of the attached press release of RNAimmune, Inc. ("**RNAimmune**"), a non-wholly owned subsidiary of the Company specializing in discovery and development of mRNA-based therapeutics and vaccines, that RNAimmune has received regulatory clearance on its Investigational New Drug (IND) application from the United States Food and Drug Administration (the "**FDA**") to commence a Phase I clinical trial for RV-1730, its SARS-CoV-2 vaccine booster candidate.

This announcement is made by the Company on a voluntary basis. The Group cannot guarantee that RV-1730 will ultimately be successfully marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Sirnaomics Ltd.
Yang (Patrick) Lu
Chairman and Executive Director

Hong Kong, April 27, 2023

As at the date of this announcement, the Board comprises Dr. Yang Lu (alias Patrick Lu), Dr. Michael V. Molyneaux, Dr. David Mark Evans and Dr. Xiaochang Dai as executive Directors, Mr. Mincong Huang and Mr. Jiankang Zhang as non-executive Directors, and Dr. Cheung Hoi Yu, Mr. Fengmao Hua, Ms. Monin Ung and Ms. Shing Mo Han, Yvonne (alias Mrs. Yvonne Law) as independent non-executive Directors.

RNAimmune Receives FDA Clearance of Investigational New Drug Application for Phase I Trial of RV-1730 COVID-19 Booster Vaccine

Germantown, MD, USA | Guangzhou, China, April 27, 2023 — RNAimmune, Inc. (the "**Company**" or "**RNAimmune**"), a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines, today announced that the Company has received a clearance from the United States Food & Drug Administration (FDA) for its Investigational New Drug (IND) application of a Phase I clinical trial for RV-1730, a SARS-CoV-2 vaccine booster candidate. The proposed clinical study will involve an evaluation of RV-1730 for its safety and prophylaxis efficacy against SARS-CoV-2 infection with people previously immunized with other mRNA-based COVID-19 vaccines. RNAimmune is the non-wholly owned subsidiary of Sirnaomics Ltd. ("**Sirnaomics**", Stock Code: 2257.HK).

During the proposed Phase I clinical study, RNAimmune will investigate the safety and efficacy of RV-1730 when administered as a single booster dose to healthy adults aged 18–55, previously vaccinated with either the Pfizer-BioNTech or Moderna COVID-19 mRNA vaccine. Participants will be treated with one of the three doses of RV-1730 at 15 μg, 30 μg or 100 μg accordingly. Investigators plan to enroll a total of 45 subjects divided into three different cohorts (15 subjects each) in the U.S. All subjects will be followed through 12 months post-vaccination for assessing RV-1730's safety and immunogenicity.

"The IND clearance from the FDA will allow us to investigate RV-1730 as an effective vaccine booster with the potential to provide continued protection against COVID-19," said Dong Shen, M.D., Ph.D., founder and President of RNAimmune. "This study is expected to provide preliminary data on the safety, tolerability, and immunogenicity of RV-1730's technology when using a vaccine construct that targets the SARS-CoV-2 variants. With further research, RNAimmune's vaccine candidate may be the focus of future studies with more contemporary variant constructs or multivalent constructs like Omicron, XBB, and other COVID-19 variants."

"Receiving FDA clearance for RV-1730 Phase I clinical as a novel COVID-19 booster vaccine marks a significant milestone for RNAimmune. As the world continues to search for effective methods of battling COVID-19, RV-1730 will provide another important option related to vaccine boosters." said Patrick Lu, Ph.D., Chairman of the board of directors of RNAimmune. "More importantly, the discovery and development efforts of RV-1730 have helped advancement of the technology platforms and regulatory capability of RNAimmune for novel mRNA-based vaccine and therapeutic product developments."

About RNAimmune

RNAimmune is an international biopharmaceutical company focusing on mRNA vaccine and therapeutics development. Its global headquarter is in Germantown, Maryland, USA, while the China headquarter is located in International BioIsland, Guangzhou. RNAimmune has received a global exclusive right to the proprietary Polypeptide Lipid Nanoparticle (PLNP) technology for mRNA delivery from Sirnaomics. In addition, RNAimmune has various independent proprietary R&D platforms, including artificial-intelligence and directed neoantigen prediction, ALEPVA algorithm for nucleic acid sequence design and lipid nanoparticle (LNP) carrier systems. RNAimmune also deployed various vaccines and therapeutics pipelines, including vaccines for infectious diseases (COVID-19, influenza, VZV and RSV etc.) and cancer vaccines (RAS, NY-ESO-1), and protein replacement medication. RNAimmune has extremely high potential and has become one of the leading companies in the field of mRNA vaccines and therapeutics. Learn more at: www.rnaimmune.com.

CONTACT:
Dong Shen, M.D., Ph.D.
President, RNAimmune, Inc.
Email: Dong.Shen@rnaimmune.com

Investor Relations:
Nigel Yip, MBA
Chief Financial Officer, RNAimmune, Inc.
Email: Nigel@rnaimmune.com

U.S. Media Contact:
Alexis Feinberg
Tel: +1 203 939 2225
Email: Alexis.Feinberg@westwicke.com

Asia Media Contact:
Heidi So
Tel: +852 2864 4826
Email: sprg_sirnaomics@sprg.com.hk